May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- Wyden and Warnock Probe Political Targeting of Non-Profits By Trump Officials
- Wyden Slams Trump Action to Target Universities Over Admissions Policy
- Wyden Slams Trump Action to Target Universities Over Admissions Policy
- Wyden, Garcia Launch Inquiry into Shady Groups Awarded $394 Million in Contracts by Trump Administration to Represent Unaccompanied Minors
- Wyden Questions Customs and Border Protection Over Favorable Treatment of Dominican Corporation’s Sugar Imports Despite Clear Evidence of Ongoing Forced Labor